© Rosalind Scientific LLC 2018-2022
© Rosalind Scientific LLC, 2018-2022
New Drug Hunter content, featured events and job postings straight to your inbox. Trusted by >3,500 drug hunters worldwide, unsubscribe anytime.
<< Back to September
first-in-class ketohexokinase (KHK) inhibitor
oral candidate in Ph. II for NAFLD/NASH
from frag.-based screening, SBDD, and opt.
J. Med. Chem., Sep. 27, 2020
Pfizer, Cambridge, MA / Groton, CT
PF-06835919 is an oral first-in-class clinical candidate for NAFLD/NASH targeting ketohexokinase (KHK), an enzyme which initiates the metabolism of fructose. The authors describe a very elegant structure-based design campaign to…
Ask your company or librarian about a Drug Hunter membership to to see all summaries and get access to even more helpful information.